Genetic Biomarkers of Sorafenib Response in Patients with Hepatocellular Carcinoma

Lydia Giannitrapani,Francesca Di Gaudio,Melchiorre Cervello,Francesca Scionti,Domenico Ciliberto,Nicoletta Staropoli,Giuseppe Agapito,Mario Cannataro,Pierfrancesco Tassone,Pierosandro Tagliaferri,Aurelio Seidita,Maurizio Soresi,Marco Affronti,Gaetano Bertino,Maurizio Russello,Rosaria Ciriminna,Claudia Lino,Francesca Spinnato,Francesco Verderame,Giuseppa Augello,Mariamena Arbitrio
DOI: https://doi.org/10.3390/ijms25042197
IF: 5.6
2024-02-13
International Journal of Molecular Sciences
Abstract:The identification of biomarkers for predicting inter-individual sorafenib response variability could allow hepatocellular carcinoma (HCC) patient stratification. SNPs in angiogenesis- and drug absorption, distribution, metabolism, and excretion (ADME)-related genes were evaluated to identify new potential predictive biomarkers of sorafenib response in HCC patients. Five known SNPs in angiogenesis-related genes, including VEGF-A, VEGF-C, HIF-1a, ANGPT2, and NOS3, were investigated in 34 HCC patients (9 sorafenib responders and 25 non-responders). A subgroup of 23 patients was genotyped for SNPs in ADME genes. A machine learning classifier method was used to discover classification rules for our dataset. We found that only the VEGF-A (rs2010963) C allele and CC genotype were significantly associated with sorafenib response. ADME-related gene analysis identified 10 polymorphic variants in ADH1A (rs6811453), ADH6 (rs10008281), SULT1A2/CCDC101 (rs11401), CYP26A1 (rs7905939), DPYD (rs2297595 and rs1801265), FMO2 (rs2020863), and SLC22A14 (rs149738, rs171248, and rs183574) significantly associated with sorafenib response. We have identified a genetic signature of predictive response that could permit non-responder/responder patient stratification. Angiogenesis- and ADME-related genes correlation was confirmed by cumulative genetic risk score and network and pathway enrichment analysis. Our findings provide a proof of concept that needs further validation in follow-up studies for HCC patient stratification for sorafenib prescription.
biochemistry & molecular biology,chemistry, multidisciplinary
What problem does this paper attempt to address?
The problem that this paper attempts to solve is to predict the differences in individual responses to sorafenib in patients with hepatocellular carcinoma (HCC) by identifying genetic biomarkers related to sorafenib response. Specifically, the researchers focused on single - nucleotide polymorphisms (SNPs) in angiogenesis - related genes and genes related to drug absorption, distribution, metabolism, and excretion (ADME), hoping to discover new potential predictive biomarkers, thereby achieving stratified treatment for HCC patients and improving the clinical application effect of sorafenib. The main objectives of the study include: 1. **Identify SNPs related to sorafenib response**: Analyze SNPs in specific genes in HCC patients to find genetic variations significantly related to the efficacy of sorafenib. 2. **Establish classification rules**: Use machine - learning methods to establish classification rules based on the detected SNPs and genotypes to distinguish between patients who respond and do not respond to sorafenib. 3. **Verify the effectiveness of biomarkers**: Further verify the effectiveness of the identified SNPs as predictive biomarkers through cumulative genetic risk score (GRS) and network - path enrichment analysis. Through these studies, the authors hope to provide a proof - of - concept, demonstrating that HCC patients can be effectively stratified by genetic biomarkers, thereby guiding the selection of personalized treatment regimens. This finding needs to be further verified in subsequent studies for clinical promotion and application.